Phase II results for Alectinib global study

Published November 23, 2015, Phase II trial results. Patients enrolled from June 2013 to April 2014. 122 evaluable patients who were all resistant to Crizotinib; overall objective response rate (ORR) of 50%. Disease Control Rate (DCR) was 79%. Median duration of response was 11.2 months.

Of 96 patients previously treated with chemotherapy the ORR was 45%.

Median progression free survival (PFS) for all patients was 8.9 months.

Central nervous system (CNS) DCR was 83%, ORR of 57%.

Alectinib remained effective longer in the brain than the body.

This entry was posted in alectinib - Alecensa from Chugai - Roche - GenenTech, Brain metastases, Lung cancer, Potential Treatments, Research, Resistance to treatment. Bookmark the permalink.

Leave a Reply